Amara Raja Energy & Mobility ARE&M

Summary

Amara Raja Energy & Mobility is India's second-largest lead-acid battery maker, and the mirror image of Exide's story in this report (see the Exide Industries report, immediately preceding this one). Its technology licence for lithium-ion cells — signed with China's Gotion High-Tech, via subsidiary GIB EnergyX, in June 2024 — came after China's technology-transfer environment had already begun tightening, and per the company's own New Energy Business head, Vikramadithya Gourineni, it "has not moved ahead due to geopolitical reasons." On the company's Q4 FY26 earnings call, Gourineni stated plainly that "sharing of technology and licensing arrangements are being increasingly discouraged by the Chinese government," and the flagship Telangana (Mahbubnagar/Divitipally) gigafactory — planned for up to 16 GWh of cells and 5 GWh of packs — has slipped from an original "before end of 2025" target to a first 2 GWh line now guided for June 2027, with full commissioning pushed to Q1 FY28.

The lead-acid core remains genuinely strong — a duopoly position alongside Exide, and a fast-scaling telecom lithium battery-pack business (cumulative supply crossed 1 GWh, with quarterly volumes exceeding 300 MWh by late FY26) that does not depend on the stalled gigafactory. But FY26 consolidated PAT declined 5.18% year-on-year to ₹895.77 crore even as the company continued investing heavily in New Energy — a combination that shows up directly in the numbers, not just the narrative. The stock fell roughly 19% during FY26, and a mid-September 2026 downgrade to "Sell" was reported in secondary coverage (the issuing brokerage was not confirmed in this research).

At a P/E near 15x, the stock is not expensive relative to Exide's roughly double that multiple — the market has already re-rated much of this bad news in. The question this report had to answer is whether that de-rating has gone far enough, or whether a still-declining earnings base, a now-multi-year-delayed capital-intensive gigafactory, and the loss of the company's stated external technology path leave room for further downside before the numbers stabilise.

Net: SELL. This is not a judgment that Amara Raja's core lead-acid franchise is impaired — it is a judgment that the New Energy segment, the part of the story the market is increasingly pricing this stock on, has just lost its clearest near-term catalyst, with the resulting capex and margin drag still largely ahead of the company rather than behind it.

• A cheap absolute valuation reflecting most of the bad news already. At ~14.9x trailing earnings — roughly half Exide's multiple — the market has already priced in much of the New Energy disappointment this report describes.
• A resilient, cash-generative lead-acid duopoly underneath the story. Alongside Exide, Amara Raja holds a dominant position in India's organised automotive and industrial battery market, largely insulated from the grid-storage-specific risks discussed elsewhere in this report.
• A genuinely scaling telecom lithium business, independent of the delayed gigafactory. Cumulative telecom lithium battery-pack supply crossed 1 GWh, with quarterly volumes exceeding 300 MWh by late FY26 — real, growing revenue that does not depend on the stalled Gotion relationship or the delayed Telangana plant.
• A lower-capital-intensity near-term BESS path. A 5 GWh BESS integration facility (~₹280 crore capex, targeted end-FY27) offers a nearer-term, less capital-intensive route into grid storage than the multi-thousand-crore gigafactory.
• A conservative balance sheet and strong credit rating. CRISIL AA+/Stable and near-zero debt mean the company is not financially stressed even as it absorbs the New Energy segment's losses — this is a valuation and timing call, not a solvency one.

• The company's own stated external technology path has failed. The Gotion/GIB EnergyX licensing deal, signed June 2024, has "not moved ahead due to geopolitical reasons" per the company's own New Energy Business head — a direct, company-sourced confirmation that the core differentiator behind the original gigafactory story did not survive contact with China's tightening technology-transfer posture.
• The flagship project has slipped by well over a year. The Telangana gigafactory's first 2 GWh line is now guided for June 2027 (from an original "before end of 2025" target), with full commissioning pushed to Q1 FY28 — a multi-quarter delay that, per this report's own cross-company reading (§9 of the primer), appears causally linked to the stalled technology relationship, though no single source draws that line explicitly.
• Consolidated profit is already declining, not merely delayed. FY26 PAT fell 5.18% year-on-year even before the gigafactory's full capital intensity has been felt — the earnings drag from this bet is still largely ahead of the company, not behind it.
• The pivot to "in-house" technology has no confirmed milestone yet. Following the stalled Gotion deal, management describes cell-chemistry R&D as now "largely driven by teams in India" via an internal facility (E Positive Energy Labs) — a strategic statement this research could not corroborate against any named technical milestone, energy-density figure or cycle-life claim.
• Recent sell-side sentiment has turned negative. A mid-September 2026 downgrade to "Sell" was reported in secondary coverage citing "flat financial performance and deteriorating technical indicators" — the issuing brokerage was not confirmed in this research, but the direction is consistent with this report's own read.
• An unresolved trademark dispute with Exide adds a further, if immaterial, overhang. Amara Raja is the respondent/appellant in the "red trade dress" case; the 2 April 2026 appellate judgment's outcome was not confirmed in this research.

• Any confirmed technical milestone for the in-house cell-chemistry programme — the clearest signal of whether the post-Gotion pivot is substantive.
• First-line commissioning at Telangana, against the current June 2027 guidance.
• Formal status of the Gotion/GIB EnergyX relationship — terminated, dormant, or still notionally active.
• 5 GWh BESS integration plant progress toward its end-FY27 target, as the nearer-term alternative story.

• Earnings-trajectory risk (dominant). FY26 PAT already declined; further New Energy capex ahead of any Telangana revenue means near-term consolidated earnings pressure is more likely to continue than reverse.
• Technology-access risk. The core lesson of this report's China-licensing comparison (§4, §7, §9 of the primer) applied unfavourably to Amara Raja specifically, and there is no confirmed alternative path yet.
• Execution/credibility risk. A second material delay to the Telangana timeline would further damage market confidence in the New Energy segment's guidance generally.
• Sentiment risk. A reported recent Sell downgrade suggests the stock may see continued technical weakness independent of fundamentals in the near term.

FY26 consolidated EPS was ₹53.02 as disclosed. We construct an indicative, not guided, FY27E EPS of approximately ₹53 (flat), reflecting continued core lead-acid and telecom-lithium growth largely offset by intensifying New Energy segment losses and capex-related costs ahead of the delayed Telangana commissioning:

Base case rounded to ₹715. The target multiple (13.5x) sits modestly below the current ~14.9x trailing multiple, reflecting the compounding effect of a confirmed stalled technology licence and a now-multi-quarter-delayed flagship project — not a further collapse in the core lead-acid business, which this report continues to view as fundamentally sound. EV/EBITDA cross-check not performed given the near-zero-debt balance sheet makes the P/E-based method the more informative single lens here. This report found a wide dispersion of third-party target prices (roughly ₹1,000 to ₹1,195 on one tracked series, and ₹1,027 to ₹1,109 on another, neither internally consistent nor clearly dated) — all of these appear to predate the confirmed Gotion-deal-stalled disclosure (BusinessToday, 22 June 2026) and are treated as stale for this report's purposes rather than averaged in.

Balance sheet and cash-flow statements are not reproduced here at full granularity. Source: company disclosures and aggregator data as compiled in this report's research digest, snapshot dated 23-25 Sep 2026.